Trial Profile
A randomised, open-label, placebo-controlled, single centre study in healthy male volunteers to explore efficacy, safety and tolerability of single doses of low molecular weight dextran sulfate (LMW-DS) in combination with recombinant human granulocyte colony stimulating factor (rhG-CSF, filgrastim) and in comparison with plerixafor treatment and placebo
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 17 Sep 2014
Price :
$35
*
At a glance
- Drugs Dextran sulfate (Primary) ; Filgrastim; Plerixafor
- Indications Stem cell mobilisation
- Focus Pharmacodynamics
- Sponsors TikoMed
- 13 Sep 2014 Status changed from recruiting to discontinued as per European Clinical Trials Database record.
- 11 Jun 2014 New trial record